BEIJING: China’s Shenzhen Stock Exchange said it is seeking further information from shopping mall operator Guangdong Highsun Group Co after Highsun announced it was backing the development of an African swine fever vaccine.
Highsun said that it would spend 900 million yuan (US$130.09mil), or 26% of its 2018 net assets, on supporting research into a natural compound the company claimed had been shown to prevent African swine fever, a disease deadly to pigs that is ravaging herds across Asia.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
